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LETTERS TO THE EDITORRegarding “How do we guarantee trainee
professional purity?”
Dr Jones (Surgical Ethics Challenges, J Vasc Surg 2009;49:790-1)
says that industry-sponsored educational programs “should always
be suspect” and “cannot help but be biased.” In so saying, Dr
Jones himself reveals a bias against industry that overlooks the fact
that their mission is identical to ours: help patients, advance science
and the practice of surgery, and make enough money to continue
to pursue our endeavors.
A new group, the Association of Clinical Researchers and
Educators, has organized to point out that far from being an
ethical morass, collaborations among the medical device and phar-
maceutical industries and vascular surgeons have been enormously
productive and beneficial to humankind. This is especially so in
vascular surgery, where an entire field of surgery has radically
changed. Industry depends on surgeon-collaborators to find out
what its engineers do not know: whether their products are appli-
cable and useful. Their feedback is invaluable to industry, and
compensation is only fair. Marketing is necessary to show surgeons
in active practice new devices and how to properly use them in their
patients. The only free time many surgeons have is at lunch, dinner,
or on weekends. Again, it is only fair to surgeons and their families
to have working conferences over meals or at facilities at locations
paid for by company representatives.
Although excesses have occurred in the past, recent industry
guidelines from trade groups like the Pharmaceutical Research and
Manufacturers of America (PhRMA) and professional groups like
the American College of Surgeons provide modern and responsi-
ble and professional guidelines that are based on transparency and
reasonable compensation for services.
Dr Jones is correct that residency directors should discuss con-
flicts of interest with residents and that evidence-based clinical reason-
ing should be foremost. Part of reasoning should include a realistic
assessment of the immense benefits of industry in medicine.
Don Nakayama, MD, FACS
Department of Surgery
Mercer University School of Medicine
Macon, Ga
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Reply
We thank Dr Nakayama for his letter. However, we do not
share his sanguine view about the medical industry. It may or may
not operate immorally within its moral system, but it has a system
of business morals that is far removed from our medical fiduciary
moral system. The goal of industry is not limited to making enough
money to “continue . . . endeavors.” A for-profit business exists
for profit. Success in business is therefore gauged by the amount of
profit. Not in medicine: our success is gauged by how well our
patients do.
“The new Association of Clinical Researchers and Educators
(ACRE) does not consider collaboration of physicians with indus-
try an ‘ethical morass,’ because medical industry has improved
medical practice, especially vascular surgery.” Beneficial outcomes
do not confer ethical immunity. Wars have improved vascular
surgery.
We agree that collaboration with industry has been enor-
mously beneficial and that collaboration with industry is not nec-
essarily an ethical morass, but only if physicians are vigilant about
protecting their professional integrity and that of trainees. Other-wise, their associations with industry can rapidly become an ethical
morass. For example, the ethical concept of medicine as a fiduciary
profession is not compatible with the reasoning that because a
surgeon is busy, an industrial salesperson should pay for his meal or
a trip. “Working conference” is often doublespeak for “I will listen
to a sales pitch for freebies.” Such self-deception cannot count as
responsible management of a physician’s economic conflicts of
interest in relationships with industry.
The recent formulation of industry guidelines by pharmaceu-
tical and medical professional organizations is offered as evidence
that there is no longer a problem. We take the opposite view: the
necessity for guidelines indicates that there is a problem. We
emphasize that these guidelines, while welcome, are not an ethical
cure. Professional integrity has the more fundamental ethical role
to play. As we mentioned in the referenced article, “The remedy for
undue industrial influence is responsible management of these
conflicts of interest, on the basis of strict adherence to fiduciary
responsibility as a matter of policy . . .”
We never indicated that collaboration with industry was in-
trinsically unethical; such collaboration, especially involving resi-
dents, is intrinsically ethically risky because of the economic con-
flicts of interest for physicians that cannot be avoided. We call to
readers’ attention the fact that the “Mission and Vision” statement
of the Association of Clinical Researchers and Educators (ACRE)
makes no mention of conflicts of interest and their responsible
management.1 Collaboration without responsible management of
conflicts of interest based on professional integrity can quickly
become corruption, a significant ethical risk that Dr Nakayama and
ACRE want us to overlook.
James W. Jones, MD, PhD, MHA
Laurence B. McCullough, PhD
Center for Medical Ethics And Health Policy
Baylor College of Medicine
Houston, Tex
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Regarding “Right subclavian pseudoaneurysm
secondary to blunt trauma in an arteriovenous
malformation”
I congratulate the author for successful management of ex-
panding pseudoaneurysm1 along the head and neck arteriovenous
malformation (AVM).
But I wonder whether this endograft would block the
feeding arteries of the coexisting AVM2 or not. Provided photos
including the Cover Image were not clear enough to show such
relationship.
If the placement of the endograft along the axillosubclavian
artery should block the feeding arteries, it would preclude future
endo-embolization of the lesion properly.3 So I would like to know
how the author would deal with this AVM lesion in its current
condition following the endograft placement.
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